Long-Term Follow up of a Randomized Phase 2 Study of Low-Dose Decitabine Versus Low-Dose Azacitidine in Lower-Risk Myelodysplastic Syndromes

Guillermo Montalban-Bravo; Elias Jabbour; Caleb Class; Nicholas J. Short; Rashmi Kanagal-Shamanna; Tapan M. Kadia; Gautam M. Borthakur; Naveen Pemmaraju; Koji Sasaki; Zeev E. Estrov; Jorge E. Cortes; Farhad Ravandi; Yesid Alvarado; Rami S. Komrokji; Mikkael A. Sekeres; David P. Steensma; Amy E. DeZern; Gail J. Roboz; Hui Yang; Hagop M. Kantarjian; Guillermo Garcia-Manero

doi:10.1182/BLOOD-2019-129141

Long-Term Follow up of a Randomized Phase 2 Study of Low-Dose Decitabine Versus Low-Dose Azacitidine in Lower-Risk Myelodysplastic Syndromes

Guillermo Montalban-Bravo, Elias Jabbour, Caleb Class, Nicholas J. Short, Rashmi Kanagal-Shamanna, Tapan M. Kadia, Gautam M. Borthakur, Naveen Pemmaraju, Koji Sasaki, Zeev E. Estrov, Jorge E. Cortes, Farhad Ravandi, Yesid Alvarado, Rami S. Komrokji, Mikkael A. Sekeres, David P. Steensma, Amy E. DeZern, Gail J. Roboz, Hui Yang, Hagop M. KantarjianGuillermo Garcia-Manero

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Blood
Volume	134
DOIs	https://doi.org/10.1182/BLOOD-2019-129141
State	Published - Nov 13 2019

Disciplines

Medicine and Health Sciences
Oncology
Survival Analysis
Internal Medicine

Access to Document

10.1182/BLOOD-2019-129141License: Unspecified

Cite this

Montalban-Bravo, G., Jabbour, E., Class, C., Short, N. J., Kanagal-Shamanna, R., Kadia, T. M., Borthakur, G. M., Pemmaraju, N., Sasaki, K., Estrov, Z. E., Cortes, J. E., Ravandi, F., Alvarado, Y., Komrokji, R. S., Sekeres, M. A., Steensma, D. P., DeZern, A. E., Roboz, G. J., Yang, H., ... Garcia-Manero, G. (2019). Long-Term Follow up of a Randomized Phase 2 Study of Low-Dose Decitabine Versus Low-Dose Azacitidine in Lower-Risk Myelodysplastic Syndromes. Blood, 134. https://doi.org/10.1182/BLOOD-2019-129141

Montalban-Bravo, G, Jabbour, E, Class, C, Short, NJ, Kanagal-Shamanna, R, Kadia, TM, Borthakur, GM, Pemmaraju, N, Sasaki, K, Estrov, ZE, Cortes, JE, Ravandi, F, Alvarado, Y, Komrokji, RS, Sekeres, MA, Steensma, DP, DeZern, AE, Roboz, GJ, Yang, H, Kantarjian, HM & Garcia-Manero, G 2019, 'Long-Term Follow up of a Randomized Phase 2 Study of Low-Dose Decitabine Versus Low-Dose Azacitidine in Lower-Risk Myelodysplastic Syndromes', Blood, vol. 134. https://doi.org/10.1182/BLOOD-2019-129141

@article{1cd949808bef4b66af2dcb014a85614a,

title = "Long-Term Follow up of a Randomized Phase 2 Study of Low-Dose Decitabine Versus Low-Dose Azacitidine in Lower-Risk Myelodysplastic Syndromes",

author = "Guillermo Montalban-Bravo and Elias Jabbour and Caleb Class and Short, {Nicholas J.} and Rashmi Kanagal-Shamanna and Kadia, {Tapan M.} and Borthakur, {Gautam M.} and Naveen Pemmaraju and Koji Sasaki and Estrov, {Zeev E.} and Cortes, {Jorge E.} and Farhad Ravandi and Yesid Alvarado and Komrokji, {Rami S.} and Sekeres, {Mikkael A.} and Steensma, {David P.} and DeZern, {Amy E.} and Roboz, {Gail J.} and Hui Yang and Kantarjian, {Hagop M.} and Guillermo Garcia-Manero",

note = "INTRODUCTION: Outcomes of pts with lower-risk MDS is heterogeneous as shown by validated prognostic scales such as the MD Anderson lower risk prognostic scoring",

year = "2019",

month = nov,

day = "13",

doi = "10.1182/BLOOD-2019-129141",

language = "American English",

volume = "134",

journal = "Blood",

}

TY - JOUR

T1 - Long-Term Follow up of a Randomized Phase 2 Study of Low-Dose Decitabine Versus Low-Dose Azacitidine in Lower-Risk Myelodysplastic Syndromes

AU - Montalban-Bravo, Guillermo

AU - Jabbour, Elias

AU - Class, Caleb

AU - Short, Nicholas J.

AU - Kanagal-Shamanna, Rashmi

AU - Kadia, Tapan M.

AU - Borthakur, Gautam M.

AU - Pemmaraju, Naveen

AU - Sasaki, Koji

AU - Estrov, Zeev E.

AU - Cortes, Jorge E.

AU - Ravandi, Farhad

AU - Alvarado, Yesid

AU - Komrokji, Rami S.

AU - Sekeres, Mikkael A.

AU - Steensma, David P.

AU - DeZern, Amy E.

AU - Roboz, Gail J.

AU - Yang, Hui

AU - Kantarjian, Hagop M.

AU - Garcia-Manero, Guillermo

N1 - INTRODUCTION: Outcomes of pts with lower-risk MDS is heterogeneous as shown by validated prognostic scales such as the MD Anderson lower risk prognostic scoring

PY - 2019/11/13

Y1 - 2019/11/13

UR - https://ashpublications.org/blood/article/134/Supplement_1/1715/427684/Long-Term-Follow-up-of-a-Randomized-Phase-2-Study

U2 - 10.1182/BLOOD-2019-129141

DO - 10.1182/BLOOD-2019-129141

M3 - Article

VL - 134

JO - Blood

JF - Blood

ER -

Long-Term Follow up of a Randomized Phase 2 Study of Low-Dose Decitabine Versus Low-Dose Azacitidine in Lower-Risk Myelodysplastic Syndromes

Disciplines

Access to Document

Other files and links

Cite this